The MED15 antibody is a research tool designed to detect MED15. a key subunit of the Mediator complex—a multi-protein assembly critical for transcriptional regulation in eukaryotes. The Mediator complex bridges transcription factors and RNA polymerase II, modulating gene expression. MED15. also known as PCQAP or ARC15. contains a conserved KID (kinase-inducible domain) that interacts with transcription factors like SMADs (in TGF-β signaling) and androgen receptor (AR), linking it to pathways involved in cancer progression, lipid metabolism, and stress responses.
MED15's role in diseases, particularly cancers (prostate, breast) and metabolic disorders (atherosclerosis), has driven interest in its study. Antibodies targeting MED15 enable researchers to investigate its expression, localization, and interactions via techniques like Western blotting, immunoprecipitation, or immunofluorescence. Commercial MED15 antibodies are typically raised in hosts such as rabbits or mice, with validation in human, mouse, or rat samples.
Studies using MED15 antibodies have revealed its overexpression in certain tumors and its regulatory effects on lipid homeostasis genes, suggesting therapeutic potential. However, antibody specificity remains a challenge due to Mediator complex heterogeneity. Researchers must validate batches using knockdown controls or epitope-tagged systems to ensure accurate detection. Overall, MED15 antibodies are pivotal for dissecting transcriptional mechanisms and disease pathways tied to this adaptable coactivator.